<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04538989</url>
  </required_header>
  <id_info>
    <org_study_id>RZ358-606</org_study_id>
    <nct_id>NCT04538989</nct_id>
  </id_info>
  <brief_title>An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital Hyperinsulinism</brief_title>
  <official_title>An Open-Label Multiple-Dose Study of RZ358 in Patients With Congenital Hyperinsulinism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rezolute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rezolute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this trial is to evaluate the safety, tolerability and glucose-raising&#xD;
      effects of RZ358 in patients with Congenital Hyperinsulinism (HI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is a significant unmet medical need to develop new therapies aimed at preventing&#xD;
      chronic recurrent hypoglycemia in congenital HI, the most common cause of persistent&#xD;
      hypoglycemia in children. RZ358 is a human mAb that allosterically attenuates excessive&#xD;
      insulin action on target cells. Therefore, RZ358 is ideally suited as a potential therapy for&#xD;
      hyperinsulinism, and it is being developed to treat the hypoglycemia associated with diseases&#xD;
      such as congenital HI. This is a Phase 2, multicenter, open label clinical study designed to&#xD;
      assess the safety and efficacy of four progressively higher doses of RZ358 in separate groups&#xD;
      of patients with hyperinsulinemic hypoglycemia due to Congenital HI, not adequately&#xD;
      controlled with or without current standard of care. A screening period of up to 5 weeks will&#xD;
      evaluate eligibility. Once enrolled, RZ358 will be administered bi-weekly over 8 weeks, and&#xD;
      then patients will complete a post-treatment follow-up period of 13 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycemic efficacy: Target glucose control</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change from Baseline in Percent Time in Glucose Target Range by Continuous Glucose Monitor (CGM)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Repeat dose safety and tolerability of RZ358</measure>
    <time_frame>Through 21 Weeks</time_frame>
    <description>Occurrence of a safety signal as assessed by the incidence of treatment-emergent AEs, SAEs, and AEs leading to study drug discontinuation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Repeat dose pharmacokinetics of RZ358</measure>
    <time_frame>Through 8 weeks</time_frame>
    <description>Change from baseline in RZ358 drug exposure as assessed by Population-PK modeling of maximum concentrations (Cmax) and Area under the Concentration-Time Curve (AUC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycemic efficacy: Occurrence of hypoglycemia</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change from Baseline in the Incidence of Hypoglycemia by Self-Monitored Blood Glucose (SMBG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic efficacy: Duration of Hypoglycemia</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change from Baseline in the Absolute (minutes) and Percent Time with Hypoglycemia by CGM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic efficacy: Occurrence of Hypoglycemia</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change from Baseline in the Incidence of Hypoglycemia by CGM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overnight Target Glucose Control</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change from Baseline in Percent Time in Overnight (midnight to 8 am) Glucose Target Range by CGM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic Efficacy: Ability to Complete a Fast without Hypoglycemia</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change from Baseline in Incidence of Hypoglycemia by SMBG, During a 12-hour Fasting Challenge</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Congenital Hyperinsulinism</condition>
  <arm_group>
    <arm_group_label>RZ358 Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>RZ358 Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>RZ358 Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>RZ358 Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RZ358 Sequential Group Cohort 1</intervention_name>
    <description>IV infusion for 8 weeks (3 mg/kg bi-weekly for 8 weeks)</description>
    <arm_group_label>RZ358 Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RZ358 Sequential Group Cohort 2</intervention_name>
    <description>IV infusion for 8 weeks (6 mg/kg bi-weekly for 8 weeks)</description>
    <arm_group_label>RZ358 Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RZ358 Sequential Group Cohort 3</intervention_name>
    <description>IV infusion for 8 weeks (9 mg/kg bi-weekly for 8 weeks)</description>
    <arm_group_label>RZ358 Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RZ358 Sequential Group Cohort 4</intervention_name>
    <description>IV infusion for 8 weeks (bi-weekly fixed dose-titration from 3 to 9 mg/kg for the first 4 weeks, followed by a fixed 9 mg/kg dose amount thereafter for the remaining 4 weeks)</description>
    <arm_group_label>RZ358 Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female age 2-45 years old (except age 12-45 in US) with an established&#xD;
             clinical diagnosis of congenital hyperinsulinism&#xD;
&#xD;
          -  Able to provide written informed consent or, as applicable, assent&#xD;
&#xD;
          -  Confirmed hypoglycemia as assessed by CGM, SMBG, and clinical evaluation, during&#xD;
             Screening&#xD;
&#xD;
          -  Willingness to use contraception if of child-bearing potential&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Out of range blood work for study entry&#xD;
&#xD;
          -  Body Mass index outside of study entry criteria&#xD;
&#xD;
          -  History of malignancy&#xD;
&#xD;
          -  Clinically significant diseases, seropositivity for HIV, hepatitis B or C antibody&#xD;
&#xD;
          -  Use of systemic corticosteroids within 30 days before Screening&#xD;
&#xD;
          -  Known or suspected allergy to the study drug&#xD;
&#xD;
          -  Recent use of an investigational drug or treatment, or participation in an&#xD;
             investigational study&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  History of drug abuse or excessive alcohol use&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Malathi Robaina</last_name>
    <phone>650-206-4507</phone>
    <email>clinicaltrials@rezolutebio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brian Roberts, M.D.</last_name>
    <email>brian@rezolutebio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Diva De Leon-crutchlow, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paul Thornton, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SHAT Children diseases &quot;Prof. Dr. Ivan Mitov&quot;</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Radka Savova, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of Varna UMHAT &quot;St. Marina&quot;</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Violeta Yotova, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Institute of the McGill University Health Centre</name>
      <address>
        <city>Monteral</city>
        <state>Qubec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>John Mitchell, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Henrik Christesen, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LTD &quot;Pediatric Surgery Centre&quot;</name>
      <address>
        <city>Tbilisi</city>
        <zip>0122</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nino Kheladze, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Magdeburg University Clinic Center (Otto-von-Guericke Universität)</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Klaus Mohnike, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Edmond &amp; Lilly Safra's Children Hospital</name>
      <address>
        <city>Ramat Gan</city>
        <state>Tel-Hashomer</state>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kineret Mazor-Aronovitch, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Endocrinology research center</name>
      <address>
        <city>Moscow</city>
        <zip>117036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maria Melikyan, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d' Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>María Clemente, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Adana Cukurova University Balcalı Hospital</name>
      <address>
        <city>Sarıçam</city>
        <state>Adana</state>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Fatih Gurbuz, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hacettepe University</name>
      <address>
        <city>Çankaya</city>
        <state>Ankara</state>
        <zip>06800</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Huseyin Demirbilek, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SBÜ Gazi Yaşargil Eğitim ve Araştirma Hastanesi</name>
      <address>
        <city>Kayapinar</city>
        <state>Diyarbakir</state>
        <zip>21070</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mehmet Özbek, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erzurum City Hospital</name>
      <address>
        <city>Yakutiye</city>
        <state>Erzurum</state>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Atilla Cayir, M. D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Antonia Dastamani, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 21, 2020</study_first_submitted>
  <study_first_submitted_qc>August 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2020</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypoglycemia</keyword>
  <keyword>Congenital Hyperinsulinism</keyword>
  <keyword>Glucose Metabolism Disorders</keyword>
  <keyword>Metabolic Diseases</keyword>
  <keyword>Pancreatic Diseases</keyword>
  <keyword>Digestive System Diseases</keyword>
  <keyword>Hyperinsulinism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Hyperinsulinism</mesh_term>
    <mesh_term>Hyperinsulinism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

